基诺美
药效团
神经母细胞瘤
化学
体内
小分子
体外
药代动力学
癌症研究
激酶
药理学
毒性
体外毒理学
结构-活动关系
药物发现
酪氨酸激酶
治疗指标
生物活性
表型筛选
作者
Maddeboina Krishnaiah,Dhananjaya Pal,Bharath Yada,Cody McHale,Sandeep Kumar Singh,Yashpal S. Chhonker,Hailey L. Dryden,Ritchie Delara,Vaidehi Mujumdar,Qi Zhang,Daryl J. Murry,Donald L. Durden
标识
DOI:10.1021/acs.jmedchem.5c01688
摘要
Our central hypothesis in this report is that the development of a single small molecule inhibitor that binds to multiple targets will be safer and more efficacious against high-risk cancers which rapidly develop resistance to one targeted therapeutic agent. We used a rational pharmacophore merging strategy and X-ray crystal structures of CDK6, CDK9, and AURKA to discover LCI133, a "first-in-class" nanomolar (nM) potent CDK4/6/9-AURKA/B inhibitor. Selectivity profiling of LCI133 using the scanMAX kinome assay of 468 kinases revealed that it is highly selective for CDK4/9 and AURKA targets. Pharmacokinetic studies with LCI133-HCl in mice demonstrate a high systemic exposure (AUC) of 7812 ng × h/mL and maximum plasma concentration (Cmax) of 3305 ng/mL. Neuroblastoma (NB) cells displayed nM sensitivity to LCI133 in vitro, and we observed potent antitumor effects in vivo in a BE(2)-C neuroblastoma xenograft model, without overt toxicity and an increase in the overall survival rate.
科研通智能强力驱动
Strongly Powered by AbleSci AI